Breaking News

Samsung Ventures Invests in Araris Biotech

Proceeds will be used to support further development and advancement of Araris’ ADC candidates.

Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, said that Samsung Venture Investment, an investment corporation established to promote the development of new technologies, has invested in the company in an independent deal ahead of its on-going series A funding. The investment was made via Samsung Life Science Fund which reflects Samsung’s commitment to further explore and expand various business opportunities in biopharmaceuticals. Ar...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters